Related Experiment Video
Updated: Aug 17, 2025
In situ Quantification of Pancreatic Beta-cell Mass in Mice
Published on: June 7, 2010
Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3
Jason Bini1, Richard E Carson2, Gary W Cline3
1PET Center, Yale University School of Medicine, New Haven, CT, USA. jason.bini@yale.edu.
Abstract:
Noninvasive quantitative imaging of beta-cells can provide information on changes in cellular transporters, receptors, and signaling proteins that may affect function and/or loss of mass, both of which contribute to the loss of insulin secretion and glucose regulation of patients with type 1 or type 2 diabetes (T1D/T2D). We have developed and optimized the use of two positron emission tomography (PET) radioligands, [18F]FP-(+)-DTBZ and [11C](+)-PHNO, targeting beta-cell VMAT2 and dopamine (D2/D3) receptors, respectively. Here we describe our optimized methodology for the clinical use of these two tracers for quantitative PET imaging of beta-cell biomarkers in vivo. We also briefly discuss our previous results and their implications and value towards extending the use of PET radioligand beyond the original goal of quantitative imaging of beta-cell mass to the potential to provide insight into the biology of beta-cell loss of mass and/or function and to evaluate the efficacy of therapeutics to prevent or restore functional beta-cell mass.
Insights
Quantitative imaging using novel positron emission tomography (PET) radioligands offers new insights into beta-cell function and mass in diabetes. This approach aids in understanding diabetes biology and evaluating therapeutic efficacy.
Area of Science:
- Endocrinology and Metabolism
- Nuclear Medicine and Imaging
- Diabetes Research
Background:
- Type 1 and type 2 diabetes (T1D/T2D) involve impaired insulin secretion and glucose regulation due to beta-cell dysfunction or loss.
- Noninvasive quantitative imaging is crucial for assessing beta-cell changes affecting diabetes progression.
Purpose of the Study:
- To describe optimized clinical methodologies for quantitative positron emission tomography (PET) imaging of beta-cell biomarkers.
- To utilize two novel PET radioligands, [18F]FP-(+)-DTBZ and [11C](+)-PHNO, targeting vesicular monoamine transporter 2 (VMAT2) and dopamine (D2/D3) receptors, respectively.
Main Methods:
- Development and optimization of clinical protocols for two PET radioligands.
- In vivo quantitative PET imaging targeting beta-cell specific biomarkers.
- Methodology focuses on VMAT2 and dopamine receptor targets within beta-cells.
Main Results:
- Established optimized methods for quantitative PET imaging of beta-cell biomarkers in vivo.
- Demonstrated the utility of [18F]FP-(+)-DTBZ and [11C](+)-PHNO for beta-cell assessment.
Conclusions:
- Quantitative PET imaging with these tracers extends beyond beta-cell mass assessment.
- This approach provides insights into the biology of beta-cell loss and function.
- Potential to evaluate therapeutic efficacy for restoring functional beta-cell mass in diabetes.
More Related Videos
09:07Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
Published on: June 11, 2020
06:52Stabilized Longitudinal In Vivo Cellular-Level Visualization of the Pancreas in a Murine Model with a Pancreatic Intravital Imaging Window
Published on: May 6, 2021